Lenvatinib en el tratamiento sistémico de primera línea en Cáncer Diferenciado de Tiroides Refractario a Radioyodo

11 / 27

• Timings of first occurrence of all grade TEAEs
Haddad I, et al. Endocrine. 2017;56:121–128.
Frequencies of these TEAEs were higher
in the earlier cycles and diminished over
the course of treatment
Median time to first onset:
12.1 weeks
Median time to first onset:
6.1 weeks
Median time to first onset:
3.0 weeks
Median time to first onset:
7.3 weeks
Median time to first onset:
5.9 weeks
Maximization of treatment results